Cited by 362Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Open access

Oxnard, Geoffrey R., Lo, Peter C., Nishino, Mizuki, Dahlberg, Suzanne E., Lindeman, Neal I., Butaney, Mohit, Jackman, David M., Johnson, Bruce E., Jänne, Pasi A.·2013·Journal of Thoracic Oncology

DOI 10.1097/jto.0b013e3182779d18PMC PMC3549533

Open this paper in CoChat — free account

Abstract

Introduction Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.Methods NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively. Clinical characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR.Results One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012. Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations. Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients. Insertion sequences were highly variable, with the most common variant (V769_D770insASV) making up only 22% of cases. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.Conclusions Patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but a poorer prognosis. The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e3182779d18

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“The identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small-cell lung cancer (NSCLC) and their association with durable responses to EGFR tyrosine kinase inhibitors (TKIs) has transformed our approach towards the use of targeted therapies in treating lung cancer.(1,2) This initial…”
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220

Flagged first, then by citations

Show all 32 references

1 of the 32 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 362

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
Pan, B., Liang, J., Shi, H., Rao, K., Guo, W., & Zhan, C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15127 · Cited by 9
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Brazel, D., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s453974 · Cited by 10
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Velázquez, A. I., & McCoach, C. E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.31 · Cited by 9
Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients
Scodes, S., & Cappuzzo, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1746646 · Cited by 10
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib
Kunimasa, K., Nishino, K., Kukita, Y., Matsumoto, S., Kawachi, H., Kawamura, T., Inoue, T., Tamiya, M., Honma, K., Sugimoto, N., et al. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.04.001 · Cited by 10
Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer
Erkin, Ö. C., Cömertpay, B., & Göv, E. (2022) · Bioinformatics and Biology Insights · doi:10.1177/11779322221088796 · Cited by 11
EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
Yang, G., Yang, Y., Hu, J., Xu, H., Zhang, S., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.984503 · Cited by 11
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Yang, J. C., Zhou, C., Janne, P. A., Ramalingam, S. S., Kim, T. M., Riely, G. J., Spira, A. I., Piotrowska, Z., Mekhail, T. M., Campelo, M. R. G., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2157815 · Cited by 9
Miliary lung metastases from non‑small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report
Sekine, A., Katano, T., Oda, T., Ikeda, S., Iwasawa, T., Satoh, H., Kataoka, T., Okudela, K., & Ogura, T. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1730 · Cited by 9
Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation
Xie, C., Kong, J., Miao, F., Wang, X., & Sheng, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13487 · Cited by 9
Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)
Si, J., Gu, X., Wang, W., Ying, S., & Song, Z. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-21-2828 · Cited by 10
Comorbidity of hypertension and lung cancer: interplay of genetics and environment
Zeng, J., Shi, D., He, D., Dong, W., Yang, Z., & Chen, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03323-3 · Cited by 8
Top advances in lung cancer, 2021
Mohindra, N. A., & Patel, J. D. (2022) · Cancer · doi:10.1002/cncr.34406 · Cited by 8
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
Ou, S. I., Lin, H. M., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Zhang, P., Nguyen, D., & Neal, J. W. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107186 · Cited by 8
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants
Hanley, M. J., Zhang, S., Griffin, R., Zhu, S. X., Fram, R. J., Lin, J., Venkatakrishnan, K., & Gupta, N. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01446-y · Cited by 8
Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity
Zhao, H., Beyett, T. S., Jiang, J., Rana, J. K., Schaeffner, I. K., Santana, J., Janne, P. A., & Eck, M. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417144121 · Cited by 8
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations
Masciale, V., Banchelli, F., Grisendi, G., Samarelli, A. V., Raineri, G., Rossi, T., Zanoni, M., Cortesi, M., Bandini, S., Ulivi, P., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107994 · Cited by 11
Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis
Mehta, A., & Vasudevan, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100398 · Cited by 8
Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion
Jiang, W., Sha, M., & Chen, C. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001504 · Cited by 8
Clinical Validation of Companion Diagnostics for the Selection of Patients with Non–Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab
Jatkoe, T. A., Wang, S., Odegaard, J. I., Roth, A. M. V., Osgood, D., Martinez, G., Lucas, P., Curtin, J. C., & Karkera, J. D. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.07.003 · Cited by 8
Amivantamab: A narrative drug review
John, A., Noronha, V., Singh, A. K., Menon, N. S., & Prabhash, K. (2023) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_166_23 · Cited by 8
Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American Society of Clinical Oncology CancerLinQ Study
Behera, M., Jiang, R., Huang, Z., Bunn, B., Wynes, M. W., Switchenko, J. M., Scagliotti, G. V., Belani, C. P., & Ramalingam, S. S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100592 · Cited by 8
EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients
Jangchul, P., Kondo, C., Shimizu, J., Horio, Y., Yoshida, K., & Hida, T. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a735cc · Cited by 8
Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes
Oxnard, G. R., & Janne, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0169 · Cited by 8
Self-citation
Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives
Li, M. S. C., Mok, K. K. S., Chan, L. L., & Mok, T. S. K. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100131 · Cited by 7
The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
Man, X., Sun, X., Chen, C., Xiang, Y., Zhang, J., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1367204 · Cited by 7
New advances in the treatment of EGFR exon20ins mutant advanced NSCLC
Yuan, C. (2025) · American Journal of Cancer Research · doi:10.62347/wtmu5537 · Cited by 8
First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review
Han, H., Zhang, X., Liu, X., Zhao, J., Zhang, J., Zhang, J., Zhu, H., Jiao, S., & Tang, H. (2023) · Medicine · doi:10.1097/md.0000000000036667 · Cited by 7
The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors
White, J. C., Pucci, P., & Crea, F. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.16 · Cited by 7
Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming
Liu, H., Qin, J., & Qian, X. (2024) · Cancer Control · doi:10.1177/10732748241292782 · Cited by 8
Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Junttila, M. R., Repellin, C. E., Salaniwal, S., Warne, R. L., Lee, Y., Kim, H., Seo, K. A., Lee, Y., Jung, H.-R., Baik, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-3502 · Cited by 6
Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations
Sangwan, K., & Agarwal, G. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01588-7 · Cited by 6
High glucose enhances the aggressiveness of lung adenocarcinoma via activating epidermal growth factor receptor/signal transducer and activator of transcription 3 pathways
Sorin, S., Zhou, Y., Thithuan, K., Khawkhiaw, K., Zeng, F., Ruangpratyakul, T., Chomphoo, S., Seubwai, W., Wongkham, S., & Saengboonmee, C. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109399 · Cited by 6
Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience
Lee, S. H., Jeong, H., Kim, D. H., Jang, S. J., Kim, S., Yoon, S., & Lee, K. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1177 · Cited by 6
A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)
Zhu, W., Pei, J., & Lu, X. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446220 · Cited by 6
Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 6
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations
Christopoulos, P., Prawitz, T., Hong, J., Lin, H. M., Hernandez, L. G., Jin, S., Tan, M., Proskorovsky, I., Lin, J., Zhang, P., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107191 · Cited by 6
Investigation of Potential Mechanisms Associated with Non-small Cell Lung Cancer
Shi, Y., Zhu, S., Yang, J., Shao, M., Ding, W., Jiang, W., Sun, X., & Yao, N. (2020) · Journal of Computational Biology · doi:10.1089/cmb.2019.0081 · Cited by 6
Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns
Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
Lu, H.-L., Jie, G., & Wu, Y.-L. L. C. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2063836 · Cited by 8
Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapy
Zhao, J., Li, M., Niu, L., Zhao, Y., & Song, X. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10289-9 · Cited by 6
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
Kim, T. M., Girard, N., Low, G. K. M., Zhuo, J., Yu, D. Y., Yang, Y., Murota, M., Lim, C. T. K., Kleinman, N. J., & Cho, B. C. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2254479 · Cited by 5
Targeting exon 20 insertion mutations in lung cancer
Yang, Y., & Wang, Y. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000919 · Cited by 5
Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
Chen, X., Zha, W., Su, M., Meng, N., Cao, S., Niu, B., & Qi, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1053805 · Cited by 5
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type
Vadagam, P., Waters, D. D., Lee, I.-Y., Chen, J., Tian, D., Near, A. M., Lyle, D., & Vanderpoel, J. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2309838 · Cited by 5
Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report
Jia, G., Bashir, S., Ye, M., Li, Y., Lai, M., Cai, L., & Xu, M. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001593 · Cited by 5
Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
Wang, L., Liu, Z., Wan, Z., Jiang, D., Zhang, M., Liu, S., & Che, N. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-383 · Cited by 5
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
Li, J., Xie, M., Zhao, R., Qiang, H., Chang, Q., Qian, J., Lu, H., Shen, Y., Han, Y., Su, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357231 · Cited by 5
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805187 · Cited by 5
Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou, S. I. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-201296rep · Cited by 5
Cutting edge therapies: A review of Food and Drug Administration‐ approved drugs for non‐small cell lung cancer
Mutukuru, M., Kandula, S. R., Ramakrishna, V., Sanka, P., Sidde, G. P., Muzzamil, S. M., Uppara, H. B., & Prasad, P. D. (2026) · International Journal of Cancer · doi:10.1002/ijc.70318 · Cited by 4
Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
Yu, L., Wang, R., Zhao, Y., Wu, Y., Wang, L., Chen, H., He, Z., Wang, Q., & Wu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231168466 · Cited by 4
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Zwierenga, F., Muntinghe-Wagenaar, M. B., Rozendal, P., Langen, A. J. D., Hendriks, L. E. L., van den Heuvel, M. M., van der Leest, C., Hashemi, S. M. S., van der Leest, P., Hiltermann, T. J. N., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01153-5 · Cited by 5
BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
Fan, F., Zhou, M., Ye, X., Mo, Z., Ma, Y., Luo, L., Liang, X., Liu, H., Weng, Y., Lin, M., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100961 · Cited by 4
[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang, X., & Zhao, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.103.01 · Cited by 4
Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations
Christopoulos, P., Girard, N., Proto, C., Soares, M., Garrido, P., van der Wekken, A. J., Popat, S., Diels, J., Schioppa, C. A., Sermon, J., et al. (2023) · Cancers · doi:10.3390/cancers15225326 · Cited by 4
High Incidence of False Positives in EGFR S768I Mutation Detection Using the Idylla qPCR System in Non-Small Cell Lung Cancer Patients
Carnero-Gregorio, M., Perera-Gordo, E., de-la-Peña-Castro, V., González-Martín, J. M., Delgado-Sánchez, J. J., & Rodríguez‐Cerdeira, C. (2025) · Diagnostics · doi:10.3390/diagnostics15030321 · Cited by 4
Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients
Garzón‐Ibáñez, M., Reyes, R., Molina‐Vila, M. Á., & Sullivan, I. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03899-w · Cited by 4
Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021
Kandemir, E. A. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221112015 · Cited by 5
A Career in Lung Cancer: Pushing Beyond Chemotherapy
Patil, P. D., Shepherd, F. A., & Johnson, D. H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239397 · Cited by 4
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
Metro, G., Giglio, A. D., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A. J., Pecci, F., Berardi, R., Cantini, L., Federico, A. D., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-9 · Cited by 4
Structure-based classification of EGFR mutations in operable pre-invasive and invasive non-small cell lung cancer: a cross-sectional study
Wang, T., Cao, J., Song, Q., Wang, L., Xiong, Y., & Chen, R. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1054 · Cited by 3
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study
Pierret, T., Greillier, L., Guisier, F., Daniel, C., Descourt, R., Galland, L., Molinier, O., Decroisette, C., Cortot, A. B., Moreau, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108766 · Cited by 3
Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy
Rosas, D., Desai, J., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093714 · Cited by 3
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation
Zhao, R., Li, J., Guo, L., Xiang, C., Chen, S., Zhao, J., Shao, J., Zhu, L., Ye, M., Qin, G., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01042-3 · Cited by 3
Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway
Cuan, X., Yang, X., Wang, J., Sheng, J., Wang, X., & Huang, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107808 · Cited by 3
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
Ikeuchi, T., Tokuyasu, H., & Ishikawa, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0927-18 · Cited by 3
Monitoring of lung malignant epithelial cells by gene methylation analysis in the conditionally reprogrammed cell cultures
Wu, G., XIAO, Y. G., FANG, F. Y., YAO, D., Liu, J., Cao, Y., Mao, Y. J., Yu, B., Yao, T., Wu, Y., et al. (2020) · Neoplasma · doi:10.4149/neo_2020_190730n690 · Cited by 3
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
Chang, G., Lam, D. C.-L., Tsai, C., Chen, Y., Shih, J., Aggarwal, S., Wang, S., Kim, S., Kim, Y., Wahid, I., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01869-0 · Cited by 3
Clinical and pathological findings of surgically resected patients for lung adenocarcinomas harboring uncommon EGFR mutations.
Yang, S., Jiang, Z., & Lu, H. (2017) · PubMed Central · Cited by 3
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system
Fu, X., Zeng, D., Li, M., Wu, J., Yang, Y., Mao, Q., Qiu, W., Huang, X., Fang, Y., Jiang, L., et al. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2471512 · Cited by 2
Navigating advanced lung cancer care, patient–physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians
Lee, C. K., Yang, X., Goto, Y., Lee, K. Y., Yim, H. S., Brooke, M., Aoshima, H., Ando, E., Liu, Y., Tsai, J., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2499511 · Cited by 2
Molecular Diagnosis, Clinical Trial Representation, and Precision Medicine in Minority Patients with Oncogene-Driven Lung Cancer
Bhatt, A., Yone, N., Lalla, M., Jeon, H., & Cheng, H. (2025) · Cancers · doi:10.3390/cancers17121950 · Cited by 3
EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics
Furuya, N. (2025) · Future Oncology · doi:10.1080/14796694.2025.2550927 · Cited by 2
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Sanborn, R. E., Zhou, C., Tang, K., Cho, B. C., Cheng, S. Y.-S., Popat, S., Ono, A., Lu, S., Majem, M., Aguilar, A., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01182-0 · Cited by 2
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis
Zhou, C., Tang, K.-J., Liu, B., Kim, S.-W., Kitazono, S., Ono, A., Thiagarajan, M., Hung, J., Boyer, M. J., Çil, T., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109302 · Cited by 2
Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR–MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083024 · Cited by 2
Tackling Lung Cancer Drug Resistance Using Integrated Drug-Repurposing Strategy
James, N., Shanthi, V., & Ramanathan, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00018-3 · Cited by 2
Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors
Chang, B.-S., Peng, T., Wu, Y., Hsieh, T., & Huang, C.-H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030404 · Cited by 2
New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
Gil‐Sierra, M. D., Briceño-Casado, M. D. P., & Cristina, M.-R. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231162545 · Cited by 2
[Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
(2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.10 · Cited by 2
Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions
Wang, H., Xu, Y., Lin, J., & Huang, Y. (2024) · Cancer Control · doi:10.1177/10732748241262190 · Cited by 2
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study
Girard, N., Park, K., Lee, S., Viteri, S., Schioppa, C. A., Diels, J., Oguz, M., Rodrigues, B., Rahhali, N., Sermon, J., et al. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100832 · Cited by 2
Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
Liu, G., Nyaw, S. F., Mok, T. S. K., Curcio, H., Cortot, A. B., Kam, T. Y., Descourt, R., Chik, Y. K. J., Cheema, P. K., Gwinnutt, J. M., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70369 · Cited by 2
Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC
Horn, M. K., Liu, K., Mathias, S. D., Colwell, H. H., Li, T. M. W. Y., Mahadevia, P. J., & Pierson, R. F. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100198 · Cited by 2
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Murano, C., Igarashi, A., Yamauchi, K., Inoue, S., & Watanabe, M. (2019) · EXCLI journal · doi:10.17179/excli2019-1786 · Cited by 2
EGFR exon 20 insertion in non-small cell lung cancer
Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2
Osimertinib in uncommon EGFR exon 21 L861R and EGFR exon 18 deletion-insertion mutant non-small cell lung cancer—case report
Wang, Y., Dorwal, P., Rajadurai, S., & Arulananda, S. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-788 · Cited by 2
A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Kim, Y. J., Kim, S., Kim, T. M., Suh, K. J., Kim, M., Kim, S. H., Keam, B., Kim, D., Lee, J. S., & Heo, D. S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107870 · Cited by 3
EGFR T790M mutation detection in NSCLC patients resistant to tyrosine kinase inhibitor therapy
Kadyrbayeva, R., Kaidarova, D., Shatkovskaya, O., Goncharova, T., Orazgaliyeva, M., & Ossikbayeva, S. (2024) · Panminerva Medica · doi:10.23736/s0031-0808.24.05172-3 · Cited by 1
Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
Shen, L., Hu, G., Wang, Y., Zhao, J., Li, X., Zhuo, J., Low, G. K. M., & Lu, S. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03826-3 · Cited by 1
Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review
Wen, Q., Zhuang, Y., Fu, S., Pan, C., Liu, Z., & Wang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1707050 · Cited by 1
Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non–Small Cell Lung Cancer: A Case Report
Morinaga, D., Furuta, M., Fukui, D., Matsuura, Y., Yoshida, Y., Ito, S., Takashima, Y., Kitai, H., Tanei, Z., Sakakibara-Konishi, J., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.01.012 · Cited by 1
Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy
Wu, J., Zhuo, J., Chen, Y.-C., Wang, S.-P., Hsieh, J.-F., & Shih, J. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.04.013 · Cited by 1
EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions
Lau, L. Y., Sahib, N. R. B. M., Cangco, C. Y. P., & Tan, A. C. (2026) · Drugs · doi:10.1007/s40265-026-02329-7 · Cited by 1
A 78-Year-Old Woman with Brain Metastases
Tafe, L. J., & Tsongalis, G. J. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.229864 · Cited by 2
Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC
Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1
Les cancers bronchiques non à petites cellules EGFR-mutés
Baldacci, S., & Cortot, A. B. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30126-4 · Cited by 1
Lektion gelernt? Die molekularen Grundlagen von Kinase‐gerichteten Therapien und Wirkstoffresistenz im nicht‐kleinzelligen Lungenkrebs
Lategahn, J., Keul, M., & Rauh, D. (2017) · Angewandte Chemie · doi:10.1002/ange.201710398 · Cited by 1
Molecular Detection of EGFR Mutation in Lung Cancer Using Bioinformatics Database with PCR Technique
Ali, A., & Ali, K. M. (2017) · Diyala Journal for Pure Science · doi:10.24237/djps.1302.211b · Cited by 1

Authors: Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A.
Affiliations: Brigham and Women's Hospital (US)
Dana-Farber Cancer Institute (US)
Corresponding author: Oxnard, Geoffrey R.
ORCID: Oxnard, Geoffrey R.
Nishino, Mizuki
Dahlberg, Suzanne E.
Lindeman, Neal I.
Butaney, Mohit
Johnson, Bruce E.
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2013-02
Volume: 8
Issue: 2
Pages: 179-184
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0b013e3182779d18
PMC: PMC3549533
OpenAlex: W2075445339
Cited by: 360
References: 32
Citations by year: 2026: 17 · 2025: 30 · 2024: 33 · 2023: 41 · 2022: 50 · 2021: 36 · 2020: 31 · 2019: 26 · 2018: 24 · 2017: 19 · 2016: 16 · 2015: 15 · 2014: 15 · 2013: 7
FWCI: 14.35
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1034 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5k23ca157631-02)
National Cancer Institute (K23-CA157631, P50CA090578, R01CA135257)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: EGFR exon 20 insertion, non-small cell lung cancer, lung adenocarcinoma, EGFR mutation, EGFR tyrosine kinase inhibitors, survival, never smokers, Asian patients, targeted therapy, molecular properties
MeSH terms: Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Exons, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Mutagenesis, Insertional, Sequence Homology, Amino Acid, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks